<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Abrocitinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Abrocitinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Abrocitinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="134856" href="/d/html/134856.html" rel="external">see "Abrocitinib: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="141009" href="/d/html/141009.html" rel="external">see "Abrocitinib: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F56524029"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious infections</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Patients treated with abrocitinib may be at increased risk for developing serious infections that may lead to hospitalization or death. The most frequent serious infections reported with abrocitinib were herpes simplex, herpes zoster, and pneumonia. If a serious or opportunistic infection develops, discontinue abrocitinib and control the infection.</p>
<p style="text-indent:0em;margin-left:2em;">Reported infections from Janus kinase (JAK) inhibitors used to treat inflammatory conditions include:</p>
<ul>
<li>
<p style="text-indent:0em;">Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease; test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test.</p></li>
<li>
<p style="text-indent:0em;">Invasive fungal infections, including cryptococcosis and pneumocystosis; patients with invasive fungal infections may present with disseminated, rather than localized, disease.</p></li>
<li>
<p style="text-indent:0em;">Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.</p></li></ul>
<p style="text-indent:0em;margin-left:2em;">Avoid use of abrocitinib in patients with an active, serious infection, including localized infections. The risks and benefits of treatment with abrocitinib should be carefully considered prior to initiating therapy in patients with chronic or recurrent infections. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with abrocitinib, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mortality</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients ≥50 years of age with at least 1 cardiovascular risk factor comparing another JAK inhibitor to tumor necrosis factor (TNF) blocker treatment, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor. Abrocitinib is not approved for use in RA patients.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancies</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Malignancies were reported in patients treated with abrocitinib. Lymphoma and other malignancies have been observed in patients receiving JAK inhibitors used to treat inflammatory conditions. In RA patients treated with another JAK inhibitor, a higher rate of malignancies (excluding nonmelanoma skin cancer) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Major adverse cardiovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Major adverse cardiovascular events were reported in patients treated with abrocitinib. In RA patients ≥50 years of age with at least 1 cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (defined as cardiovascular death, myocardial infarction [MI], and stroke), was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue abrocitinib in patients that have experienced a MI or stroke.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombosis</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients treated with abrocitinib. Thrombosis, including PE, DVT, and arterial thrombosis have been reported in patients receiving JAK inhibitors used to treat inflammatory conditions. Many of these adverse reactions were serious and some resulted in death. In RA patients ≥50 years of age with at least 1 cardiovascular risk factor treated with another JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers. Avoid abrocitinib in patients at risk. If symptoms of thrombosis occur, discontinue abrocitinib and treat appropriately.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56617618"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cibinqo</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57136912"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cibinqo</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F56524032"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Janus Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F56587171"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Do not initiate therapy in patients with active serious infection (including localized infection, tuberculosis, hepatitis B and/or C), a platelet count &lt;150,000/mm<sup>3</sup>, an absolute lymphocyte count &lt;500 cells/mm<sup>3</sup>, an ANC &lt;1,000 cells/mm<sup>3</sup>, or Hb &lt;8 g/dL. Complete all age-appropriate immunizations before initiating therapy; avoid administering live vaccines immediately prior to, during, and immediately after therapy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1cb01b0a-9408-444e-899b-06d8a273579d">Atopic dermatitis, refractory, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis, refractory, moderate to severe: Note:</b> Not recommended for use with biologic immunomodulators, other Janus kinase inhibitors, or other systemic immunosuppressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32492087','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32492087','lexi-content-ref-manu.1'])">Ref</a></span>). May be used with or without topical corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">US labeling: Initial: 100 mg once daily. For insufficient response, may increase dose to 200 mg once daily. Discontinue treatment if inadequate response is seen after dose increase.</p>
<p style="text-indent:-2em;margin-left:6em;">Canadian labeling: Initial: Adults &lt;65 years of age: 100 to 200 mg once daily; in patients taking 200 mg once daily, consider decreasing dose to 100 mg once daily if symptom control is achieved by week 12; may increase back to 200 mg once daily if symptom control cannot be maintained. Maximum dose: 200 mg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Dosage recommendations for CYP2C19 poor metabolizers:</i>
<b> Oral: </b>Initial: 50 mg once daily. For insufficient response, may increase dose to 100 mg once daily. Discontinue treatment if inadequate response is seen after dose increase.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses: </i>Administer missed dose as soon as possible within 12 hours of scheduled dose. If &lt;12 hours until the next scheduled dose, skip the missed dose and resume dosing at regular scheduled time.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56587173"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Renal function estimated using the MDRD formula for dose adjustment purposes.</p>
<p style="text-indent:-2em;margin-left:2em;">US labeling:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 30 to &lt;60 mL/minute: 50 mg once daily. For insufficient response, may increase dose to 100 mg once daily. Discontinue treatment if inadequate response is seen after dose increase.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute, end-stage renal disease: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients on renal replacement therapy: Use is not recommended (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Canadian labeling:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;60 mL/minute: Reduce dose by 50%.</p></div>
<div class="block doha drugH1Div" id="F56587174"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Turcotte-Pugh class A and B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Turcotte-Pugh class C): Avoid use (has not been studied).</p></div>
<div class="block dot drugH1Div" id="F56587175"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematologic toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Platelet count &lt;50,000/mm<sup>3</sup>: Discontinue use and monitor CBC until platelet count &gt;100,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">Absolute lymphocyte count &lt;500/mm<sup>3</sup>: Interrupt therapy until absolute lymphocyte count ≥500/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">ANC &lt;1,000/mm<sup>3</sup>: Interrupt therapy until ANC ≥1,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemoglobin &lt;8 g/dL: Interrupt therapy until hemoglobin ≥8 g/dL.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Infection (severe or opportunistic): </b>Discontinue abrocitinib and treat infection. Consider risks and benefits of continuing abrocitinib prior to reinitiating therapy.</p></div>
<div class="block doe drugH1Div" id="F56587172"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">US labeling: Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">Canadian labeling: ≥65 years of age: Initial dose: 100 mg once daily.</p></div>
<div class="block dop drugH1Div" id="F57957821"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="141009" href="/d/html/141009.html" rel="external">see "Abrocitinib: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Do not initiate therapy in patients with active serious infection (including localized infection, tuberculosis, hepatitis B and/or C), a platelet count &lt;150,000/mm<sup>3</sup>, an absolute lymphocyte count (ALC) &lt;500 cells/mm<sup>3</sup>, an ANC &lt;1,000 cells/mm<sup>3</sup>, or Hb &lt;8 g/dL. Complete all age-appropriate immunizations before initiating therapy; avoid administering live vaccines immediately prior to, during, and immediately after therapy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1cb01b0a-9408-444e-899b-06d8a273579d">Atopic dermatitis, refractory, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis, refractory, moderate to severe:</b> Children ≥12 years and Adolescents: Oral: 100 mg once daily; for insufficient response after 12 weeks of therapy, may increase dose to 200 mg once daily. Maximum daily dose: 200 mg/<b>day</b>. If response remains inadequate after dose increase to 200 mg, discontinue therapy. <b>Note:</b> May be used in combination with topical steroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34406366','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34406366','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosage recommendations for CYP2C19 poor metabolizers:</i> Children ≥12 years and Adolescents: Oral: Initial: 50 mg once daily; for insufficient response after 12 weeks of therapy, may increase dose to 100 mg once daily. If response remains inadequate after dose increase to 100 mg, discontinue therapy.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Hematologic toxicity:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Platelet count &lt;50,000/mm<sup>3</sup>: Discontinue use and monitor CBC until platelet count &gt;100,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:8em;">ALC &lt;500/mm<sup>3</sup>: Interrupt therapy until ALC ≥500/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:8em;">ANC &lt;1,000/mm<sup>3</sup>: Interrupt therapy until ANC ≥1,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:8em;">Hemoglobin &lt;8 g/dL: Interrupt therapy until hemoglobin ≥8 g/dL.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Infection (severe or opportunistic): </b>Discontinue abrocitinib and treat infection. Consider risks and benefits of continuing abrocitinib prior to reinitiating therapy.</p></div>
<div class="block dorp drugH1Div" id="F57957825"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Children ≥12 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 30 to &lt;60 mL/minute: Initial: 50 mg once daily. For insufficient response after 12 weeks, may increase dose to 100 mg once daily. If response remains inadequate after dose increase, discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute, end-stage renal disease: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients on renal replacement therapy: Use is not recommended (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F57957828"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is not recommended (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F56772549"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular/thrombotic events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Major cardiovascular/thrombotic events, including <b>acute myocardial infarction</b>, <b>cerebrovascular accident</b>, <b>deep vein thrombosis</b>, and <b>pulmonary embolism </b>(PE) have been reported in patients receiving abrocitinib.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; unknown. Dose-related events of venous thromboembolism occurred in patients treated with abrocitinib (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34406619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34406619'])">Ref</a></span>) though Janus kinase (JAK) inhibitors may reduce the risk for cardiovascular disease via inhibition of JAK-dependent cytokines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33761207']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33761207'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Current or past smokers</p>
<p style="text-indent:-2em;margin-left:6em;">• Existing cardiovascular or thrombotic risk factors (ie, previous PE, recent hospitalization) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34406619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34406619'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (ie, 200 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34406619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34406619'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">An increased incidence of <b>infection</b> (including <b>serious infection </b>[eg,<b> pneumonia</b>]) has been demonstrated with abrocitinib. Opportunistic infection, including <b>herpes simplex infection</b> and <b>herpes zoster infection</b> have also been reported, including herpes virus reactivation. Invasive fungal infections, tuberculosis, and other bacterial and viral infections have been reported with other nonselective Janus kinase (JAK) inhibitors, although JAK1-selective inhibitors are thought to be less likely to result in opportunistic infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34406619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34406619'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Abrocitinib inhibits activity of the JAK1 enzymes, which block signaling of type 1 and type 2 interferons and cytokines which are necessary for lymphocyte development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34406619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34406619'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (ie, 200 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34406619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34406619'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic infection, recurrent infection, or history of serious or opportunistic infection (ie, tuberculosis, hepatitis B virus, herpes virus)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying conditions that may predispose to infection</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancies</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib is a Janus kinase inhibitor; therefore, use may result in malignancies, including lymphomas. <b>Nonmelanoma skin cancer</b> (NMSC) has been rarely reported with abrocitinib.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to the pharmacologic action. Janus kinase (JAK) inhibition interferes with T and NK cells and interferon function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29282366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29282366'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed; most cases of NMSC occurred in the first 3 months of abrocitinib treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34406619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34406619'])">Ref</a></span>). <b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Known malignancy (other than successfully treated NMSC)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56535355"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adolescents and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (6% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (35%; serious infection: ≤1% [including pneumonia])<span class="lexi-table-link-container"> (<a aria-label="Infection table link" class="lexi-table-link" data-table-id="lexi-content-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infection')">table 1</a>)</span><span class="table-link" style="display:none;">Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Infection" frame="border" id="lexi-content-infection" rules="all">
<caption style="text-align:center;">
<b>Abrocitinib: Adverse Reaction: Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Abrocitinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Abrocitinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">590</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">342</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">608</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">342</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serious infection: 1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">608</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">342</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serious infection: 0.3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">590</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">342</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (9% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (2% to 5%), contact dermatitis (1%), impetigo (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (1%), gastroenteritis (1%), upper abdominal pain (≤2%), vomiting (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (3% to 4%, including reactivation of disease), herpes zoster infection (≤1%, including reactivation of disease), influenza (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (2% to 3%), fatigue (1% to 2%), headache (6% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatinine phosphokinase in blood specimen (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Oropharyngeal pain (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, deep vein thrombosis, pulmonary embolism</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperlipidemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocytopenia, malignant neoplasm (including nonmelanoma skin cancer [basal cell carcinoma of skin, cutaneous T-cell lymphoma, squamous cell carcinoma]) (Simpson 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Retinal detachment</p></div>
<div class="block coi drugH1Div" id="F56524035"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of antiplatelet therapy, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to abrocitinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F56587154"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic toxicity: Hematologic toxicity, including thrombocytopenia and lymphopenia, has been observed in patients treated with abrocitinib.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid abnormalities: Dose-dependent increases in lipid parameters (eg, total cholesterol, low-density lipoprotein cholesterol, triglycerides) have been observed in patients treated with abrocitinib.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Avoid use in patients with severe hepatic impairment or those with active hepatitis B or hepatitis C.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Avoid use in patients with severe renal impairment or end-stage renal disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2C19 poor metabolizers: Dose reduction recommended in patients who are known or suspected to be CYP2C19 poor metabolizers due to reduced metabolic clearance of abrocitinib.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Complete all age-appropriate immunizations before initiating therapy; avoid administration of live vaccines immediately prior to, during, and immediately after therapy.</p></div>
<div class="block foc drugH1Div" id="F56617619"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cibinqo: 50 mg, 100 mg, 200 mg</p></div>
<div class="block geq drugH1Div" id="F56617617"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56695235"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cibinqo Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $222.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $222.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $222.69</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57136913"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cibinqo: 50 mg, 100 mg, 200 mg</p></div>
<div class="block adm drugH1Div" id="F56587176"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food. Swallow tablet whole; do not crush, split, or chew.</p></div>
<div class="block admp drugH1Div" id="F57957830"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food. Swallow tablet whole; do not crush, split, or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses: </i>Administer missed dose as soon as possible within 12 hours of scheduled dose. If &lt;12 hours until the next scheduled dose, skip the missed dose and resume dosing at regular scheduled time.</p></div>
<div class="block meg drugH1Div" id="F56574168"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Cibinqo: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F213871s004lbl.pdf%23page%3D27&amp;token=GqyjMMpxFLjNCZKeeZfAZDGOOlzCjVcauP2Oue4TMq7P39DnJxKbZS3zk50d5hyiZl0%2BfRBAxMp7GtIfs04Bi7Gxi%2Ft9YA31B8mK5VSw3n3WwUHoilWUWQFqRXnTbBdw&amp;TOPIC_ID=134831" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213871s004lbl.pdf#page=27</a></p></div>
<div class="block use drugH1Div" id="F56524034"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis, refractory, moderate to severe:</b> Treatment of refractory, moderate to severe atopic dermatitis in adults and pediatric patients ≥12 years of age whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Not recommended for use in combination with other Janus kinase inhibitors, biologic immunomodulators, or other immunosuppressants.</p></div>
<div class="block cyt drugH1Div" id="F56560173"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2B6 (minor), CYP2C19 (major), CYP2C9 (major), CYP3A4 (minor), OAT1/3; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> P-glycoprotein/ABCB1</p></div>
<div class="block dri drugH1Div" id="F56560170"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of Abrocitinib. Management: Do not use antiplatelet drugs with abrocitinib during the first 3 months of abrocitinib therapy. The abrocitinib prescribing information lists this combination as contraindicated. This does not apply to low dose aspirin (81 mg/day or less).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anifrolumab: Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) may enhance the immunosuppressive effect of Anifrolumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: May enhance the antiplatelet effect of Abrocitinib. Management: Do not use aspirin at doses greater than 81 mg/day with abrocitinib during the first 3 months of abrocitinib therapy. The abrocitinib prescribing information lists this combination as contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with P-glycoprotein (P-gp) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the immunosuppressive effect of Abrocitinib. Management: The use of abrocitinib in combination with other immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Moderate): May decrease the serum concentration of Abrocitinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Strong): May decrease the serum concentration of Abrocitinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Moderate): May increase the serum concentration of Abrocitinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inducers (Moderate): May decrease the serum concentration of Abrocitinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Digoxin.  Management: Measure digoxin serum concentrations before initiating treatment with these P-glycoprotein (P-gp) inhibitors. Reduce digoxin concentrations by either reducing the digoxin dose by 15% to 30% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May increase the serum concentration of Abrocitinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): Abrocitinib may enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): Abrocitinib may enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): Abrocitinib may enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin tablets with P-glycoprotein/ABCB1 inhibitors. If concomitant use is required, monitor for lefamulin adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Abrocitinib may enhance the immunosuppressive effect of Methotrexate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the antiplatelet effect of Abrocitinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rimegepant.  Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Abrocitinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Abrocitinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F56587152"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were observed in some animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than abrocitinib are preferred for the treatment of atopic dermatitis in pregnant patients (Vestergaard 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to abrocitinib is ongoing. Health care providers are encouraged to enroll patients exposed to abrocitinib during pregnancy in the Pregnancy Registry (877-311-3770). Patients may also enroll themselves.</p></div>
<div class="block brc drugH1Div" id="F56587153"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if abrocitinib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 1 day after the last abrocitinib dose.</p></div>
<div class="block mop drugH1Div" id="F56587178"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC (prior to initiating therapy, 4 weeks after initiation, 4 weeks after dose increase, and periodically thereafter in patients who develop hematologic abnormalities); lipid parameters (4 weeks after initiating therapy and periodically thereafter); tuberculosis (TB) screen (baseline and annually thereafter for patients in highly endemic areas for TB); viral hepatitis screening (prior to initiating therapy and periodically thereafter); clinical signs/symptoms of infection (including TB) during and after therapy; skin examinations (periodically, in patients at increased risk for skin cancer); signs/symptoms of thrombosis.</p></div>
<div class="block pha drugH1Div" id="F56587157"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Abrocitinib reversibly inhibits the Janus kinase 1 (JAK1) enzyme by blocking the adenosine triphosphate binding site. Inhibition of JAK1 prevents signaling of interleukin-4, interleukin-13, and other cytokines involved in the pathogenesis of atopic dermatitis (Bieber 2021).</p></div>
<div class="block phk drugH1Div" id="F56587158"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: &gt;91%.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~100 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~64% (primarily albumin).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP2C19 (~53%), CYP2C9 (~30%), CYP3A4 (~11%), and CYP2B6 (~6%). Metabolized to 2 active metabolites (3-hydroxypropyl [less active than parent] and 2-hydroxypropyl [as active as parent]).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~60%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Abrocitinib and active metabolites: 3 to 5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ≤1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;1% as unchanged drug; active metabolites predominantly excreted in urine).</p></div>
<div class="block phksp drugH1Div" id="F56587167"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with moderate (eGFR 30 to 59 mL/minute) and severe (eGFR &lt;30 mL/minute) renal impairment, AUC of abrocitinib and its active metabolites was increased by 110% and 191%, respectively, compared to subjects with normal renal function (eGFR ≥90 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function: In patients with mild (Child-Pugh class A) and moderate (Child-Pugh class B) hepatic impairment, AUC of abrocitinib and its active metabolites was increased by ~4% and ~15%, respectively, compared to patients with normal hepatic function.</p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 poor metabolizers: AUC of abrocitinib was 2.3-fold higher in poor metabolizers compared to normal metabolizers.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56556137"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cibinqo</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33761207">
<a name="33761207"></a>Bieber T, Simpson EL, Silverberg JI, et al; JADE COMPARE Investigators. Abrocitinib versus placebo or dupilumab for atopic dermatitis. <i>N Engl J Med</i>. 2021;384(12):1101-1112. doi:10.1056/NEJMoa2019380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abrocitinib-drug-information/abstract-text/33761207/pubmed" id="33761207" target="_blank">33761207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cibinqo.2">
<a name="Cibinqo.2"></a>Cibinqo (abrocitinib) [prescribing information]. New York, NY: Pfizer Labs; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cibinqo.1">
<a name="Cibinqo.1"></a>Cibinqo (abrocitinib) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34406366">
<a name="34406366"></a>Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. <i>JAMA Dermatol</i>. 2021;157(10):1165-1173. doi:10.1001/jamadermatol.2021.2830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abrocitinib-drug-information/abstract-text/34406366/pubmed" id="34406366" target="_blank">34406366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29282366">
<a name="29282366"></a>Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. <i>Nat Rev Drug Discov</i>. 2017;17(1):78. doi:10.1038/nrd.2017.267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abrocitinib-drug-information/abstract-text/29282366/pubmed" id="29282366" target="_blank">29282366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32492087">
<a name="32492087"></a>Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. <i>JAMA Dermatol</i>. 2020;156(8):863-873. doi:10.1001/jamadermatol.2020.1406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abrocitinib-drug-information/abstract-text/32492087/pubmed" id="32492087" target="_blank">32492087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34406619">
<a name="34406619"></a>Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. <i>Am J Clin Dermatol</i>. 2021;22(5):693-707. doi:10.1007/s40257-021-00618-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abrocitinib-drug-information/abstract-text/34406619/pubmed" id="34406619" target="_blank">34406619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31231864">
<a name="31231864"></a>Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>J Eur Acad Dermatol Venereol</i>. 2019;33(9):1644-1659. doi:10.1111/jdv.15709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abrocitinib-drug-information/abstract-text/31231864/pubmed" id="31231864" target="_blank">31231864</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 134831 Version 60.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
